Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Cognizant Communication Corporation
About the journal
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is a journal published by Cognizant Communication Corporation in United States. It is listed in MEDLINE and PUBMED according to the sources read. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Cognizant Communication Corporation
- ISSN
- 0965-0407 · 1555-3906
- Country
- United States
- Access
- Not open access / not declared
Index listings
- MEDLINE · 1992-01-01
- PUBMED · 2016-01-21
- Indexing
- MEDLINE · PUBMED
- APC
- —
- Declared review time (DOAJ)
- —
- Actual review time (measured)
- 92 days received→accepted — computed from PubMed (n=91)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
2130
Last recorded publication year
2026
h-index
68
i10-index
1101
From OpenAlex open data (CC0).
Editorial & policy4
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- Portico
- Open references deposited at Crossref
- 42%
- ORCID iDs in current deposits
- 0%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
Identity & continuity3
- Alternate titles
- Oncology research incorporating anti-cancer drug design,
- Source type
- journal
- NLM unique ID (PubMed)
- 9208097
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Cancer-related molecular mechanisms research
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- MicroRNA in disease regulation
- Circular RNAs in diseases
- Circular RNAs in diseases
- RNA modifications and cancer
- RNA modifications and cancer
Show all subjects (50)
- Ferroptosis and cancer prognosis
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- RNA Research and Splicing
- RNA Research and Splicing
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Cancer-related gene regulation
- Cancer-related gene regulation
- Cancer-related Molecular Pathways
- Cancer-related Molecular Pathways
- Cancer Mechanisms and Therapy
- Epigenetics and DNA Methylation
- Epigenetics and DNA Methylation
- Cancer Mechanisms and Therapy
- Immune cells in cancer
- Wnt/β-catenin signaling in development and cancer
- Immune cells in cancer
- Cell death mechanisms and regulation
- Wnt/β-catenin signaling in development and cancer
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Cell death mechanisms and regulation
- Ubiquitin and proteasome pathways
- Ubiquitin and proteasome pathways
- PI3K/AKT/mTOR signaling in cancer
- PI3K/AKT/mTOR signaling in cancer
- Immunotherapy and Immune Responses
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- Cancer therapeutics and mechanisms
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Peptidase Inhibition and Analysis
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ